Results 31 to 40 of about 4,378 (208)

Tropomyosin 3 Gene Fusions in Cancers: From Mechanisms to Treatments-A Comprehensive Review. [PDF]

Cancer Med
ABSTRACT Background Tropomyosin 3 (TPM3), one of the four tropomyosin genes, is predominantly expressed in eukaryotic cells. As a crucial regulatory protein, TPM3 associates with actin within thin myofilaments, thereby playing an essential role in the regulation of muscle contraction.
Chen A, Li S, Guo C, Gu C, Gui J, Deng Y, Feng X, Mi Y.   +7 more
europepmc   +2 more sources

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion

Clinical Case Reports, 2021
Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer.
Fabián Pitoia
doaj   +1 more source

Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report

Case Reports in Oncology, 2021
While neurotrophic tropomyosin receptor kinase (NTRK) fusions represent rare oncogenic drivers (<1% of solid cancers), the recent approval of NTRK inhibitors (larotrectinib and entrectinib) led to dramatic responses in patients with NTRK fusion ...
Tyler Lanman, Melanie Hayden Gephart, Nam Bui, Angus Toland, Seema Nagpal   +4 more
doaj   +1 more source

NTRK-A narrative review

Cancer Research, Statistics, and Treatment, 2021
Lung cancer diagnostics and therapeutics have witnessed a paradigm shift in the last decade because of the discovery of targetable biomarkers and rapid approvals of the corresponding targeted therapies.
Ullas Batra, Shrinidhi Nathany, Mansi Sharma   +2 more
doaj   +1 more source

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients

Current Oncology, 2021
Neurotrophic tyrosine receptor kinase gene fusions (NTRK) are oncogenic drivers present at a low frequency in most tumour types (80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and considered mutually exclusive with other ...
Sébastien Perreault, Rose Chami, Rebecca J. Deyell, Dina El Demellawy, Benjamin Ellezam, Nada Jabado, Daniel A. Morgenstern, Aru Narendran, Poul H. B. Sorensen, Jonathan D. Wasserman, Stephen Yip   +10 more
doaj   +1 more source

NTRK Somatic Fusions and Tumor Agnostic Treatment in Pediatric Cancers

Journal of Contemporary Medicine, 2022
Neurotrophic tyrosine receptor kinase (NTRK) gene rearrangements have been recently identified and developed as one of the biomarkers that have been utilized as new targets for cancer therapy.
Emel Ünal, Sonay İncesoy Özdemir, Ayça Yağmur Şimşek   +2 more
doaj   +1 more source

Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. [PDF]

J Clin Oncol
Mascarenhas L, DuBois SG, Albert CM, Bielack S, Orbach D, Federman N, Geoerger B, Nagasubramanian R, Zhang Y, Chisholm J, Melcon SG, Goto H, Morgenstern DA, Owens C, Pappo AS, Perreault S, Schulte JH, Shukla N, Zwaan CM, Neu N, Bernard-Gauthier V, De La Cuesta E, van Tilburg CM, Laetsch TW.   +23 more
europepmc   +3 more sources

Larotrectinib in a NTRK‐rearranged soft tissue sarcoma in the neoadjuvant setting: A case report

Clinical Case Reports, 2021
Patients with soft tissue sarcomas should be assessed for neurotrophic tropomyosin receptor kinase (NTRK) gene fusions as neoadjuvant treatment with larotrectinib may prevent amputation.
Catherine Percy, Thomas Schubert, Christine Galant, Thomas Kirchgesner, Filomena Mazzeo   +4 more
doaj   +1 more source

NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report

Frontiers in Oncology, 2023
Background: Neurotrophic tyrosine receptor kinase (NTRK) gene-fusion targeted molecules revolutionized the paradigm of treatment of a limited subgroup of cancers of various histologies.
Emanuela Palmerini, Giorgio Frega, Marco Gambarotti, Tommaso Frisoni, Marilena Cesari, Alberto Bazzocchi, Marco Miceli, Davide Maria Donati, Davide Maria Donati, Stefano Fanti, Cristina Nanni, Stefania Benini, Alessandra Longhi, Anna Paioli, Andrea Marrari, Rossella Hakim, Alberto Righi, Toni Ibrahim   +17 more
doaj   +1 more source

Molecular Landscape in Infant High-Grade Gliomas: A Single Center Experience

Diagnostics, 2022
High-grade gliomas (HGG) represent about 15% of all pediatric brain tumors, with a dismal prognosis and survival rates ranging from 15 to 35%. Approximately 10–12% of pediatric HGGs (pHGG) occur in children younger than five years of age at diagnosis ...
Valentina Di Ruscio, Andrea Carai, Giada Del Baldo, Maria Vinci, Antonella Cacchione, Evelina Miele, Sabrina Rossi, Manila Antonelli, Sabina Barresi, Massimo Caulo, Giovanna Stefania Colafati, Angela Mastronuzzi   +11 more
doaj   +1 more source